MedTrace Logo

IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

NCT07257640 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-10

No results posted yet for this study

Summary

This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.

Conditions

Interventions

DRUG

IL-5 CAR-T cells

Each subject receive IL-5 CAR T-cells by intravenous infusion

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • He Huang, MD · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2028-11-30
Completion
2028-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07257640 on ClinicalTrials.gov